Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Association of IFI200 Gene Polymorphisms with Susceptibility to Systemic Lupus Erythematosus

INGORN KIMKONG, YINGYOS AVIHINGSANON and NATTIYA HIRANKARN
The Journal of Rheumatology July 2010, 37 (7) 1544-1547; DOI: https://doi.org/10.3899/jrheum.091255
INGORN KIMKONG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YINGYOS AVIHINGSANON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NATTIYA HIRANKARN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: fmednpt{at}md.chula.ac.th
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

To the Editor:

The MNDA (myeloid nuclear differentiation antigen), IFIX (interferon-inducible protein X), IFI16 (interferon-inducible protein 16), and AIM2 (absent in melanoma 2) are a group of interferon (IFN)-inducible genes whose products belong to the gene family denoted hematopoietic interferon-inducible protein with 200 amino acid repeat (IFI200). These genes map on chromosome 1q21–23, which is the major susceptibility locus of systemic lupus erythematosus (SLE). They are proposed as new candidate genes for SLE susceptibility for several reasons: (1) genetic mapping from a murine model of lupus1,2; (2) upregulation of all 4 genes in patients with SLE3; (3) the role of IFI16 as autoantigen in patients with SLE4,5; (4) the ability of IFI16 to bind single-strand DNA in a process of DNA repair6; and (5) the discovery of AIM2 as an intracellular DNA sensor leading to inflammation and apoptosis7. Therefore, IFI200 might be associated with abnormal inflammation and loss of tolerance to dsDNA observed in patients with SLE.

We recruited 200 SLE patients (194 women, 6 men; mean age 36.21 ± SD 10.76 yrs) from King Chulalongkorn Memorial Hospital, Bangkok, each having at least 4 of the American College of Rheumatology revised criteria for SLE8, and 200 ethnically matched healthy volunteer blood donors from the Thai Red Cross Society (147 women, 53 men; mean age 23 ± SD 12.3 yrs)9. The study was approved by the ethics committee of the Faculty of Medicine, Chulalongkorn University, and all subjects gave their informed consent.

Detection of apoptosis

Within 60 minutes after blood draw, peripheral blood mononuclear cells (PBMC) from 15 healthy donors containing different IFI16 genotypes were isolated by Ficoll-Hypaque gradient (Robbins Scientific, Sunnyvale, CA, USA) and resuspended in RPMI-1640 medium (Sigma, New York, NY, USA) with 10% fetal bovine serum (Gibco, Karlsruhe, Germany) and 100 U/ml penicillin (Gibco) and 100 μg/ml streptomycin (Gibco) at concentration 5 × 106 cells/ml. These cells were plated into 24-well plastic tissue culture plates. PBMC were treated with doxorubicin (Pharmacia and Upjohn GmbH, Freiburg, Germany) at a concentration of 10 μg/ml and then cultured at 37°C in 5% CO2 for 24 h. This condition was determined to be effective to induce highest p53 expression in dose (1, 10, and 100 μg/ml) and time (8 and 24 h) response experiments. p53 mRNA expression was studied using real-time reverse transcription-polymerase chain reaction (RT-PCR) with the following primers: 5′TGG CCA TCT ACA AGC AGT CAC A3′ and 5′GCA AAT TTC CTT CCA CTC GGA T3′, as described10. Finally, the percentage of apoptotic cells was measured by FACScan flow cytometry (Becton Dickinson, Mountain View, CA, USA) for annexin V-FITC and propidium iodide binding according to the manufacturer’s protocol (BD Biosciences Pharmingen, San Diego, CA, USA). Cells positive only for annexin V were counted as apoptotic.

Quantification of IFIX and IFI16 isoforms

Expression of IFIX and IFI16 isoforms was semiquantified by conventional RT-PCR using the following primers: 5′GGA ACA GAG TCA GCA TCC and 5′GTT ATT TGA TAT CCT TGT CC for IFIX 11; and 5′CAT CTT CGG ACT CCT CAG and 5′GTT CAG CAC CAT CAC TTC for IFI16. cDNA from leukocytes of 19 SLE patients containing different genotypes was amplified in a Perkin Elmer/GeneAmp PCR 2400 system. The PCR conditions consisted of initial denaturation at 94°C for 5 min, followed by 30 cycles of denaturation (94°C, 30 s), annealing (60°C for IFIX gene, 62°C for IFI16 gene, 30 s), extension (72°C, 30 s), and final extension (72°C, 7 min). PCR products were loaded in 1.5% Tris-acetate agarose gel and analyzed by electrophoresis in Tris-acetate buffer at 100 volts for 40 min followed by staining with 50 μg/ml ethidium bromide. The density of product bands was semiquantified using Gel Doc™ MZL software (Bio-Rad).

Statistical analysis

The association between genotypes and the expression of isoforms or apoptosis was analyzed by GraphPad Prism, version 4.0 (Graph-Pad Software, San Diego, CA, USA). The Mann-Whitney U test was used in comparisons between 2 groups, while Kruskal-Walls H was applied in case of analysis of more than 2 groups. A p value < 0.05 was considered significant.

Eleven putative functional single-nucleotide polymorphisms (SNP) were selected from MNDA, IFIX, IFI16, and AIM2 genes according to computational prediction and genotyped as described in Table 1. The percentage of genotyping for each SNP was 100%. There were no missing genotyping data. All SNP were in Hardy-Weinberg equilibrium when we compared the observed with the expected genotype frequencies of each SNP (p > 0.05). PLINK v1.05 program12 was used to calculate p values, empirical p values (100,000 permutations), and odds ratios (95% confidence intervals) for genotype and haplotype associations. Linkage disequilibrium was determined by JLIN, a Java-based linkage disequilibrium plotter13 (Table 2).

View this table:
  • View inline
  • View popup
Table 1.

Putative functional single-nucleotide polymorphisms (SNP) and genotyping methods.

View this table:
  • View inline
  • View popup
Table 2.

Linkage disequilibrium coefficients (D’ and r2) among single-nucleotide polymorphisms (SNP) within MNDA, IFIX, IFI16, and AIM2.

A significant association of the minor allele frequency from 3 SNP of IFIX and IFI16 genes was found between SLE patients and healthy controls (Table 3). The G13792T (rs856084) in IFIX and the C6771G (rs866484) and A23201G (rs1772414) in IFI16 showed significant differences (OR 0.73, 95% CI 0.54–0.98, empirical p = 0.033; OR 1.33, 95% CI 1.00–1.75, empirical p = 0.05; and OR 1.37, 95% CI 1.03–1.80, empirical p = 0.030, respectively). The association of both SNP (rs866484 and rs1772414) in IFI16 gene seems to be a recessive effect model. The presence of 2 G alleles (GG) conferred a significant p = 0.009 (empirical p = 0.023) for rs866484 and p = 0.013 (empirical p = 0.032) for rs1772414. The marginal significance results are probably due to the limited sample size in this study. We performed haplotype analysis of significant SNP rs866484 and rs1772414 with the strongest linkage disequilibrium (D’ = 0.814 and r2 = 0.643) by comparing each haplotype with another 3 haplotypes between SLE patients and controls. Our finding showed that the GG was a risk haplotype (OR 1.41 and p = 0.017, empirical p = 0.031), whereas CA was a protective haplotype (OR 0.73 and p = 0.032, empirical p = 0.041).

View this table:
  • View inline
  • View popup
Table 3.

Genotype and allele frequencies for MNDA, IFIX, IFI16, and AIM2 polymorphisms in SLE patients and healthy controls. Significant results (p value < 0.05) indicated in bold type.

Regarding the selection as putative functional SNP, we tried to prove our hypothesis of 3 positive SNP as follows. SNP rs866484 (C6771G) of IFI16 is a nonsynonymous SNP whose amino acid is altered from threonine to serine. This SNP is located on an A-type repeat containing p53 binding site. Binding of IFI16 protein to the C-terminus of p53 has been reported to stimulate the transcription of p53-responsive reporter plasmids and leads to susceptibility to apoptosis of cells14. We hypothesized that the G risk allele may bind p53 with higher affinity and lead to more apoptosis. We conducted our experiment by inducing the highest p53 mRNA expression with doxorubicin at a concentration of 10 μg/ml for 24 h. The association of SNP rs866484 and apoptosis rate was studied by flow cytometry analysis. We were unable to determine the association between SNP and apoptosis (Figure 1A). This negative finding may be because threonine and serine are in the same amino acid group. Nevertheless, further study should be performed using direct protein-protein interaction methods to prove the direct role of this SNP in protein structure that affects p53 binding. In addition, we tested the association of the 2 SNP within the intron of IFIX (rs856084) and IFI16 (rs1772414) genes with the expression of the isoforms (α and ß for IFIX; A, B, and C for IFI16) by reverse transcription-polymerase chain reaction, as described3. However, we found no differences in isoforms among the genotypes (Figure 1B, 1C, 1D).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

A. The effect of SNP rs866484 genotypes (CC, CG, and GG; n = 5, 6, and 5, respectively) on apoptotic response of healthy PBMC treated with 10 μg/ml doxorubicin for 24 h. B, C, D. The ratio of short product/full-length product grouped by SNP rs856084 genotypes of IFIX (GG, GT, and TT; n = 3, 9, and 3) and SNP rs1772414 genotypes of IFI16 (AA, AG, and GG; n = 7, 6, and 6). Each data symbol represents an individual sample; horizontal lines show median values.

Our results suggest that these SNP are not likely to be functional SNP. We could not exclude the possibility that these SNP are in linkage disequilibrium with nearby causative SNP. Interestingly, one report in SLE in Caucasian patients also suggested an association signal in the IFIX-IFI16 intergenic region15. More extensive research using dense SNP and increased sample sizes is required to clarify the role of IFIX and IFI16 gene in SLE.

Footnotes

  • Supported in part by a research grant from the Lupus Research Unit, the 90th Year Anniversary of Chulalongkorn University (Ratchadaphiseksomphot Endownment Fund) and the National Research Council of Thailand 2008–2009.

    REFERENCES

    1. 1.↵
      1. Rozzo SJ,
      2. Allard JD,
      3. Choubey D,
      4. Vyse TJ,
      5. Izui S,
      6. Peltz G,
      7. et al.
      Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 2001;15:435–43.
      OpenUrlCrossRefPubMed
    2. 2.↵
      1. Choubey D,
      2. Panchanathan R
      . Interferon-inducible Ifi200-family genes in systemic lupus erythematosus. Immunol Lett 2008;119:32–41.
      OpenUrlCrossRefPubMed
    3. 3.↵
      1. Kimkong I,
      2. Avihingsanon Y,
      3. Hirankarn N
      . Expression profile of HIN200 in leukocytes and renal biopsy of SLE patients by real-time RT-PCR. Lupus 2009;18:1066–72.
      OpenUrlAbstract/FREE Full Text
    4. 4.↵
      1. Seelig HP,
      2. Ehrfeld H,
      3. Renz M
      . Interferon-gamma-inducible protein p16. A new target of antinuclear antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1994;37:1672–83.
      OpenUrlCrossRefPubMed
    5. 5.↵
      1. Mondini M,
      2. Vidali M,
      3. Airo P,
      4. De Andrea M,
      5. Riboldi P,
      6. Meroni PL,
      7. et al.
      Role of the interferon-inducible gene IFI16 in the etiopathogenesis of systemic autoimmune disorders. Ann NY Acad Sci 2007;1110:47–56.
      OpenUrlCrossRefPubMed
    6. 6.↵
      1. Yan H,
      2. Dalal K,
      3. Hon BK,
      4. Youkharibache P,
      5. Lau D,
      6. Pio F
      . RPA nucleic acid-binding properties of IFI16-HIN200. Biochim Biophys Acta 2008;1784:1087–97.
      OpenUrlPubMed
    7. 7.↵
      1. Fernandes-Alnemri T,
      2. Yu JW,
      3. Datta P,
      4. Wu J,
      5. Alnemri ES
      . AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009;458:509–13.
      OpenUrlCrossRefPubMed
    8. 8.↵
      1. Tan EM,
      2. Cohen AS,
      3. Fries JF,
      4. Masi AT,
      5. McShane DJ,
      6. Rothfield NF,
      7. et al.
      The 1982 American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
      OpenUrlPubMed
    9. 9.↵
      1. Hirankarn N,
      2. Avihingsanon Y,
      3. Wongpiyabovorn J
      . Genetic susceptibility to SLE is associated with TNF-alpha gene polymorphism −863, but not −308 and −238, in Thai population. Int J Immunogenet 2007;34:425–30.
      OpenUrlCrossRefPubMed
    10. 10.↵
      1. Yu L,
      2. Domann FE
      . Rapid and direct quantitative RT-PCR method to measure promoter activity. Biotechnol Prog 2006;22:1461–3.
      OpenUrlPubMed
    11. 11.↵
      1. Ding,
      2. et al.
      2004.
    12. 12.↵
      1. Purcell S,
      2. Neale B,
      3. Todd-Brown K,
      4. Thomas L,
      5. Ferreira MA,
      6. Bender D,
      7. Maller J,
      8. et al.
      PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559–75.
      OpenUrlCrossRefPubMed
    13. 13.↵
      1. Carter KW,
      2. McCaskie PA,
      3. Palmer LJ
      . JLIN: a Java based linkage disequilibrium plotter. BMC Bioinformatics 2006;7:60.
      OpenUrlCrossRefPubMed
    14. 14.↵
      1. Johnstone RW,
      2. Wei W,
      3. Greenway A,
      4. Trapani JA
      . Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16. Oncogene 2000;19:6033–42.
      OpenUrlCrossRefPubMed
    15. 15.↵
      1. Fernando MM,
      2. Rigby RJ,
      3. Roberton CA,
      4. Rioux JD,
      5. Vyse TJ
      . Interferon-inducibile genes on chromosome 1 contribute to lupus susceptibility. Rheumatology 2006;45:i15–i16.
      OpenUrlFREE Full Text
    PreviousNext
    Back to top

    In this issue

    The Journal of Rheumatology
    Vol. 37, Issue 7
    1 Jul 2010
    • Table of Contents
    • Table of Contents (PDF)
    • Index by Author
    • Editorial Board (PDF)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about The Journal of Rheumatology.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Association of IFI200 Gene Polymorphisms with Susceptibility to Systemic Lupus Erythematosus
    (Your Name) has forwarded a page to you from The Journal of Rheumatology
    (Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Association of IFI200 Gene Polymorphisms with Susceptibility to Systemic Lupus Erythematosus
    INGORN KIMKONG, YINGYOS AVIHINGSANON, NATTIYA HIRANKARN
    The Journal of Rheumatology Jul 2010, 37 (7) 1544-1547; DOI: 10.3899/jrheum.091255

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

     Request Permissions

    Share
    Association of IFI200 Gene Polymorphisms with Susceptibility to Systemic Lupus Erythematosus
    INGORN KIMKONG, YINGYOS AVIHINGSANON, NATTIYA HIRANKARN
    The Journal of Rheumatology Jul 2010, 37 (7) 1544-1547; DOI: 10.3899/jrheum.091255
    del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
    • Tweet Widget
    •  logo
    Bookmark this article

    Jump to section

    • Article
      • Detection of apoptosis
      • Quantification of IFIX and IFI16 isoforms
      • Statistical analysis
      • Footnotes
      • REFERENCES
    • Figures & Data
    • Info & Metrics
    • References
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Dr. Murakami et al reply
    • PPI Use and Its Significant Association With an Increased Incidence of Intestinal Behçet Disease
    • Dr. Gensler et al reply
    Show more Letters

    Similar Articles

    Content

    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology

    Resources

    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies

    Subscribers

    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions

    More

    • About Us
    • Contact Us
    • My Alerts
    • My Folders
    • Privacy/GDPR Policy
    • RSS Feeds
    The Journal of Rheumatology
    The content of this site is intended for health care professionals.
    Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
    Print ISSN: 0315-162X; Online ISSN: 1499-2752
    Powered by HighWire